Portal de Periódicos da CAPES

Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

2012; Public Library of Science; Volume: 9; Issue: 4 Linguagem: Inglês

10.1371/journal.pmed.1001200

1549-1676

V. Beral, C Hermon, Richárd Pető, G. Reeves, Louise A. Brinton, P. Marchbanks, Eva Negri, R. B. Ness, P.H.M. Peeters, Martin Vessey, Eugenia E. Calle, Susan M. Gapstur, Alpa V. Patel, Luigino Dal Maso, R. Talamini, Angela Chetrit, Galit Hirsh‐Yechezkel, Flora Lubin, Siegal Sadetzki, Naomi E. Allen, Diana Bull, Karen A. Callaghan, B Crossley, Kezia Gaitskell, A. Goodill, J Green, Timothy J. Key, Kath Moser, R. Collins, R. Doll, Carlos A. González, N. Lee, H. W. Ory, Herbert B. Peterson, Phyllis A. Wingo, N Martin, Tieng Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, Supawat Chutivongse, P. Jimakorn, Pramuan Virutamasen, Chansuda Wongsrichanalai, Anne Tjønneland, Linda Titus‐Ernstoff, T. Byers, Thomas E. Rohan, Berit Jul Mosgaard, D. Yeates, Jo L. Freudenheim, Jenny Chang‐Claude, R. Kaaks, Kenneth E. Anderson, Aaron R. Folsom, Kim Robien, Mary Anne Rossing, D. B. Thomas, Nathalie Weiss, Elio Ríboli, Françoise Clavel‐Chapelon, Daniel W. Cramer, Susan E. Hankinson, Shelley S. Tworoger, Silvia Franceschi, Carlo La Vecchia, Cecilia Magnusson, T. Riman, Elisabete Weiderpass, Alicja Wolk, Leo J. Schouten, Piet A. van den Brandt, N Chantarakul, Suporn Koetsawang, D. Rachawat, Domenico Palli, Amanda Black, Amy Berrington de González, Louise A. Brinton, D. Michal Freedman, Patricia Hartge, Ann W. Hsing, J. Lacey, R. N. Hoover, Catherine Schairer, Sidsel Graff‐Iversen, Randi Selmer, Chris Bain, A. C. Green, David M. Purdie, Victor Siskind, Penelope M. Webb, Susan E. McCann, P. C Hannaford, C Kay, Colin Binns, A H Lee, Min Zhang, R. B. Ness, Philip C. Nasca, Patricia F. Coogan, Julie R. Palmer, Lynn Rosenberg, Jennifer L. Kelsey, Ralph S. Paffenbarger, Alice S. Whittemore, Klea Katsouyanni, A. Trichopoulou, D Trichopoulos, A. Tzonou, Alfredo Dabancens, L. Martinez, Ramiro Molina, O Salas, Marc T. Goodman, Galina Lurie, Michael E. Carney, Lynne R. Wilkens, Linda Hartman, Jonas Manjer, Håkan Olsson, Jeane Ann Grisso, Todd M. Morgan, James E. Wheeler, J. Casagrande, M C Pike, R K Ross, Ancong Wu, Anthony B. Miller, Merethe Kumle, Eiliv Lund, Linda McGowan, X-O Shu, Wei Zheng, T. M M Farley, Susan Holck, O. Meirik, H. A. Risch,

Endometrial and Cervical Cancer Treatments

Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships.Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p=0.02) in ever-users of hormone therapy.Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade. Please see later in the article for the Editors' Summary.